Genmab A/S (NASDAQ:GMAB) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lessened its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,935,224 shares of the company's stock after selling 200,928 shares during the quarter. Alliancebernstein L.P. owned approximately 2.26% of Genmab A/S worth $311,698,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Brandywine Global Investment Management LLC acquired a new stake in Genmab A/S during the fourth quarter valued at approximately $33,804,000. Two Sigma Advisers LP grew its position in shares of Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after purchasing an additional 280,900 shares during the last quarter. JPMorgan Chase & Co. increased its position in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after acquiring an additional 394,670 shares during the period. FMR LLC lifted its position in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares during the period. Finally, LPL Financial LLC lifted its holdings in shares of Genmab A/S by 3.3% during the 4th quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after acquiring an additional 6,288 shares during the period. 7.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

GMAB has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Truist Financial dropped their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday. Finally, William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $41.33.

Genmab A/S Stock Performance

Shares of GMAB traded down $0.85 during mid-day trading on Friday, reaching $18.39. The stock had a trading volume of 2,472,572 shares, compared to its average volume of 984,925. The firm has a market cap of $12.17 billion, a price-to-earnings ratio of 10.57, a PEG ratio of 2.65 and a beta of 1.07. The business has a fifty day moving average of $20.67 and a 200 day moving average of $21.61. Genmab A/S has a 12 month low of $18.30 and a 12 month high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.